Skip to main content

Clinical trial IJB_2691

Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Organ Kidney
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor BMS - Bristol Myers Squibb int.
EudraCT Identifier 2016-004502-34
Inclusion criteria "Adjuvant", healthy margin
Last update